U *click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Ulipristal acetate (Esmya®) (824/13)	Pre-operative treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. The duration of treatment is limited to three months.	Formulary GPs may prescribe under the direction of Gynaecology	125	Mar/Apr 2013
Ulipristal acetate (EllaOne®) (599/10)	Emergency contraception	Formulary	96 95	Apr/May 2010 Feb/Mar 2010
Ulipristal acetate, 5mg, tablet (Esmya®) 1128/16	For the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from clinical experts – decision expected by April 2016	154	May 2015
Umeclidinium (Incruse®) (1004/14)	COPD	Non-formulary - absence of clinician demand	144	Jan/Feb 2015
Umeclidinium/vilanterol (Anoro®) (978/14)	Maintenance bronchodilatore treatment to relieve symptoms in adults with COPD	Non-formulary - absence of clinician demand	146 140	Feb 2015 Jul/Aug 2014
Upadacitinib 15mg prolonged-release tablets (Rinvoq®) SMC2532	For the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	192	April 2023

	drugs (nsaids). Upadacitinib offers an additional treatment choice in the therapeutic class of immunosuppressants.			
Upadacitinib 15mg prolonged-release tablets (Rinvoq®) SMC2495	For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). Upadacitinib may be used as monotherapy or in combination with methotrexate. SMC restriction: in adults with moderate disease (a disease activity score [DAS28] of 3.2 to 5.1) when intensive therapy with 2 or more conventional dmards has not controlled the disease well enough. In a phase III randomised, placebo-controlled and active comparator study in patients who had an inadequate response to methotrexate, upadacitinib significantly improved the signs and symptoms of RA compared with placebo.	Available in line with national guidance for prescribing	192	April 2023
Upadacitinib 15mg prolonged-release tablet (Rinvoq®) SMC2480	For the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Upadacitinib 15mg, 30mg, and 45mg prolonged-release tablets (Rinvoq®) SMC2510	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Upadacitinib 15mg and 30mg prolonged-release tablets (Rinvoq®) SMC2417	For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. SMC restriction: patients who have had an inadequate response to at least one conventional systemic immunosuppressant such as ciclosporin, or in whom such	Available in line with national guidance		

	treatment is considered unsuitable.			
Upadacitinib 15mg prolonged-release tablets (Rinvoq®) SMC2361	For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate. SMC restriction: for use in patients with psoriatic arthritis whose disease has not responded adequately to at least two conventional DMARDs (cDMARDs), given either alone or in combination. Upadacitinib offers an additional treatment choice in the therapeutic class of Janus Kinase (JAK) inhibitors in this setting.	Available in line with local guidance	185	July 2021
Upadacitinib 15mg prolonged-release tablet (Rinvoq®) SMC2315	For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate. SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs and in patients with severe disease inadequately controlled by a TNF antagonist in whom rituximab is not appropriate.	Available in line with local guidance	183	March 2021
Upadacitinib 15mg, 30mg and 45mg prolonged-release tablets (Rinvoq®) SMC2575	For the treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
Urokinase (Syner-KINASE®)	Lysis of blood clots	HOSPITAL ONLY	66	2006

Ursodeoxycholic acid 500mg film-coated tablets (Ursofalk®) (889/13)	For the dissolution of cholesterol gallstones in the gall bladder. The gallstones must not show as shadows on X-ray images and should not exceed 15mm in diameter. The gall bladder must be functioning despite the gallstone(s). For the treatment of primary biliary cirrhosis (PBC), provided there is no decompensated hepatic cirrhosis.	Non-Formulary - lack of clinician demand Non drug techniques preferred Formulary	129	Aug/Sep 2013
Ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (vials) and solution for injection in pre-filled syringe (Stelara®) SMC 2250	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. In a phase III study in patients with moderate to severe ulcerative colitis who had failed prior therapy, clinical remission was achieved by a significantly greater proportion of patients who received ustekinumab compared with placebo	Available in line with local guidance for prescribing	180	Sept 2020
Ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara®) SMC No. (1250/17)	For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies.	Available in line with national guidance	163	Sep 2017
Ustekinumab 45mg solution for injection and prefilled syringe (Stelara®) SMC No. 1115/15	Treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to,	Formulary	153	Jan/Feb 2016

	other systemic therapies or phototherapies. SMC Restriction: continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.	Hospital Use Only (Paediatric Dermatology Clinic)		
Ustekinumab (Stelara®) (944/14)	Active psoriatic arthritis in adults	HOSPITAL ONLY	136	Mar/Apr 2014
Ustekinumab (Stelara®) (572/09)	Moderate to severe plaque psoriasis	HOSPITAL ONLY	100 95	Oct/Nov 2010 Feb/Mar 2010

Updated:6th December 2023

Back to top Back to homepage